Extracellular Vesicles from Human Urine-Derived Stem Cells Prevent Osteoporosis by Transferring CTHRC1 and OPG
Chun-Yuan Chen,Shan-Shan Rao,Yi-Juan Tan,Ming-Jie Luo,Xiong-Ke Hu,Hao Yin,Jie Huang,Yin Hu,Zhong-Wei Luo,Zheng-Zhao Liu,Zhen-Xing Wang,Jia Cao,Yi-Wei Liu,Hong-Ming Li,Yang Chen,Wei Du,Jiang-Hua Liu,Yan Zhang,Tuan-Hui Chen,Hao-Ming Liu,Ben Wu,Tao Yue,Yi-Yi Wang,Kun Xia,Peng-Fei Lei,Si-Yuan Tang,Hui Xie
DOI: https://doi.org/10.1038/s41413-019-0056-9
IF: 12.7
2019-01-01
Bone Research
Abstract:Osteoporosis is a debilitating bone disease affecting millions of people. Here, we used human urine-derived stem cells(USCs),which were noninvasively harvested from unlimited and easily available urine, as a "factory" to obtain extracellular vesicles(USCEVs) and demonstrated that the systemic injection of USC-EVs effectively alleviates bone loss and maintains bone strength in osteoporotic mice by enhancing osteoblastic bone formation and suppressing osteoclastic bone resorption. More importantly, the anti-osteoporotic properties of USC-EVs are not notably disrupted by the age, gender, or health condition(with or without osteoporosis) of the USC donor. Mechanistic studies determined that collagen triple-helix repeat containing 1(CTHRC1) and osteoprotegerin(OPG) proteins are enriched in USC-EVs and required for USC-EV-induced pro-osteogenic and anti-osteoclastic effects. Our results suggest that autologous USC-EVs represent a promising novel therapeutic agent for osteoporosis by promoting osteogenesis and inhibiting osteoclastogenesis by transferring CTHRC1 and OPG.